La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

BioRestorative Therapies Croissance future

Future contrôle des critères 2/6

BioRestorative Therapies devrait augmenter ses bénéfices et ses revenus de 57.9% et de 77.8% par an respectivement, tandis que le BPA devrait croître de croître de 52.8% par an.

Informations clés

57.9%

Taux de croissance des bénéfices

52.8%

Taux de croissance du BPA

Biotechs croissance des bénéfices	28.5%
Taux de croissance des recettes	77.8%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	25 Sep 2024

Mises à jour récentes de la croissance future

Recent updates

BioRestorative begins enrollment in mid-stage study of stem cell therapy for lumbar disk disease

Jun 30

Prévisions de croissance des bénéfices et des revenus

NasdaqCM:BRTX - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	3	-20	N/A	N/A	2
12/31/2025	3	-16	N/A	N/A	2
12/31/2024	1	-13	N/A	N/A	2
6/30/2024	0	-4	-7	-7	N/A
3/31/2024	0	-5	-6	-6	N/A
12/31/2023	0	-10	-7	-6	N/A
9/30/2023	0	-15	-7	-6	N/A
6/30/2023	0	-17	-7	-7	N/A
3/31/2023	0	-16	-7	-7	N/A
12/31/2022	0	-13	-6	-6	N/A
9/30/2022	0	-35	-6	-5	N/A
6/30/2022	0	-34	-5	-5	N/A
3/31/2022	0	-33	-4	-4	N/A
12/31/2021	0	-44	-3	-3	N/A
9/30/2021	0	-30	-3	-3	N/A
6/30/2021	0	-26	-3	-3	N/A
3/31/2021	0	-19	-2	-2	N/A
12/31/2020	0	-11	-2	-2	N/A
9/30/2020	0	-7	-3	-3	N/A
6/30/2020	0	-11	-4	-4	N/A
3/31/2020	0	-18	-5	-5	N/A
12/31/2019	0	-15	-7	-7	N/A
9/30/2019	0	-17	-7	-7	N/A
6/30/2019	0	-15	-6	-6	N/A
3/31/2019	0	-14	-6	-6	N/A
12/31/2018	0	-13	-5	-5	N/A
9/30/2018	0	-11	-5	-5	N/A
6/30/2018	0	-10	-4	-4	N/A
3/31/2018	0	-9	N/A	-4	N/A
12/31/2017	0	-9	N/A	-4	N/A
9/30/2017	0	-10	N/A	-4	N/A
6/30/2017	0	-9	N/A	-4	N/A
3/31/2017	0	-9	N/A	-5	N/A
12/31/2016	0	-9	N/A	-5	N/A
9/30/2016	0	-10	N/A	-5	N/A
6/30/2016	0	-9	N/A	-4	N/A
3/31/2016	0	-9	N/A	-4	N/A
12/31/2015	1	-8	N/A	-3	N/A
9/30/2015	1	-6	N/A	-3	N/A
6/30/2015	1	-6	N/A	-3	N/A
3/31/2015	1	-6	N/A	-3	N/A
12/31/2014	0	-6	N/A	-3	N/A
9/30/2014	0	-6	N/A	-3	N/A
6/30/2014	0	-6	N/A	-3	N/A
3/31/2014	0	-6	N/A	-3	N/A
12/31/2013	0	-6	N/A	-3	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: BRTX devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: BRTX devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: BRTX devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de BRTX ( 77.8% par an) devrait croître plus rapidement que le marché US ( 8.8% par an).

Croissance élevée des revenus: Le chiffre d'affaires de BRTX ( 77.8% par an) devrait croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de BRTX devrait être élevé dans 3 ans

BioRestorative Therapies Croissance future

Future contrôle des critères 2/6

Informations clés

Mises à jour récentes de la croissance future

Consensus revenue estimates increase by 72%

Consensus revenue estimates increase by 20%, EPS downgraded

Consensus EPS estimates upgraded to US$1.96 loss

Consensus revenue estimates increase by 12%

Consensus revenue estimates increase by 105%

Recent updates

Consensus revenue estimates increase by 72%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

BioRestorative Therapies, Inc., Annual General Meeting, Sep 19, 2024

BioRestorative Therapies, Inc. to Report Q2, 2024 Results on Aug 13, 2024

BioRestorative Therapies, Inc. Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program

BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice Due to Failure to Timely File its Quarterly Report on Form 10-Q for the Fiscal Quarter Ended March 31, 2024

BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice Due to Failure to Timely File its Quarterly Report on Form 10-Q for the Fiscal Quarter Ended March 31, 2024

BioRestorative Therapies, Inc. announced delayed 10-Q filing

BioRestorative Therapies, Inc. Enhances Preclinical Metabolic Program with A Novel Exosome-Based Biologic Targeting Obesity

BioRestorative Therapies, Inc. to Report Q1, 2024 Results on May 14, 2024

Consensus revenue estimates increase by 20%, EPS downgraded

BioRestorative Therapies, Inc. Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment

BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease

Consensus EPS estimates upgraded to US$1.96 loss

Full year 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Shareholder dilution

Consensus revenue estimates increase by 12%

BioRestorative Therapies Presents Promising Data At Orthopaedic Research Society 2024 Annual Meeting

BioRestorative Therapies, Inc. Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease

New minor risk - Share price stability

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 105%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

BioRestorative Therapies, Inc., Annual General Meeting, Sep 13, 2023

Biorestorative Therapies Inc. Receives License from New York State

BioRestorative Therapies, Inc. announced that it expects to receive $2.07565 million in funding

BioRestorative Therapies, Inc. Receives Unanimous Recommendation to Proceed in Its Phase 2 Clinical Trial for Chronic Lumbar Disc Disease, BRTX-100

BioRestorative Therapies, Inc. Receives Notice of Allowance by the Japanese Patent and Trademark Office for Patent Application Related to Its Thermostem Program

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

BioRestorative Therapies and Northwell Health Enter into Agreement to Participate in the Phase 2 Clinical Trial

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Biorestorative Therapies Announces Notice of Allowance by the European Patent Office for Patent Related to Its Thermostem(R) Program

BioRestorative Therapies Inc. Announces SBIR Phase I Grant to Explore the Therapeutic Effects of ThermoStem Targeting Polycystic Ovary Syndrome as an Indication

Third quarter 2022 earnings released: US$1.28 loss per share (vs US$4.99 loss in 3Q 2021)

High number of new and inexperienced directors

BioRestorative Therapies, Inc., Annual General Meeting, Nov 03, 2022

BioRestorative Therapies, Inc. Announces First Patient Enrolled for the Company's Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease

BioRestorative begins enrollment in mid-stage study of stem cell therapy for lumbar disk disease

Biorestorative Therapies, Inc. Announces Clinical Trial Contract with Second Site for the Company’S Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (Cldd)

BioRestorative Therapies Announces Clinical Site Initiation for the Company's Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease

BioRestorative Therapies, Inc. Announces Selection of 10 Clinical Sites for its Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease

Biorestorative Therapies Announces It Has Initiated Its Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease – Site Selection Underway

BioRestorative Therapies Announces Notice of Allowance for New Patent Application in Japan and Expansion of ThermoStem® IP Portfolio

BioRestorative Therapies, Inc. Announces Filing of Ten Patent Applications Related to its BRTX-100 Program

BioRestorative Therapies, Inc. Receives Notice of Allowance for Patent Application in Israel for Its Metabolic Program

BioRestorative Therapies Receives Patent in Japan Related to its Off-the-Shelf ThermoStem® Program

BioRestorative Therapies, Inc. announced delayed annual 10-K filing

Biorestorative Therapies, Inc. Elects Nickolay Kukekov as Director

BioRestorative Therapies, Inc. Announces Board Changes

BioRestorative Therapies, Inc. announced that it has received $0.6 million in funding

First Amended Joint Reorganization Plan and Disclosure Statement Filed by BioRestorative Therapies, Inc.

Interim DIP Financing Approved for BioRestorative Therapies, Inc.

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance